Bottom Line: Defining the operational imperative difference between commercial hospitals and federal facilities clearly necessitates the strategic development of separate, tailored value propositions for each market The American hospital landscape presents pharmaceutical manufacturers with two fundamentally different economic realities: one dictated by the margin drivers of commercial hospitals and the other by the cost containment mandate of federally owned facilities. Both

Bottom Line: To transform federal grant wins into a strategic tool, manufacturers must overcome internal siloing and ensure the funds secured support precise pharmacoeconomic evidence within the federal health system. Pharmaceutical and medical device manufacturers routinely underestimate the strategic importance of federally-funded grants in their core market access strategy for the Department of Veterans Affairs (VA) and the Department of Defense (DoD). Although a generally

Bottom Line: Given the structural complexity of the federal healthcare system - direct, compliant engagement with key stakeholders is an essential for high-value insights necessary for product success. Amidst the diverse channels of U.S. healthcare delivery, the Veteran Affairs Medical Centers (VAMCs) and Military Treatment Facilities (MTFs) serve as a concentrated point of care for millions of veterans and active-duty personnel. For pharma manufacturers, targeted direct enga

Bottom Line: The VA's Share My Health Data (SMHD) app is a strategic digital asset that transforms episodic care into continuous insight by aggregating standardized, high-quality Patient-Generated Health Data (PGHD), offering the VA a unique pathway to accelerated high-value real-world evidence (RWE) generation specific to its patient population. The U.S. Department of Veterans Affairs' (VA) Share My Health Data (SMHD) app is an interesting evolution in how the VA is transfor

Bottom Line: The VA/DoD procurement model provides pharmaceutical manufacturers with a predictable, efficient, and simplified channel advantage by using the statutory Federal Ceiling Price (FCP) and a direct-purchase, single-payer structure that eliminates complex negotiations, post-sale rebates, and private intermediaries. The procurement model utilized by the nation's largest integrated healthcare systems, the Department of Veterans Affairs (VA) and the Department of Defens

Bottom Line: The consistent healthcare coverage and high patient commitment inherent in the service-disabled veteran status population create a uniquely stable, integrated market that offers reliable utilization and measurable returns for manufacturers. Service-disabled veteran status is more than an administrative label. It is the foundation of one of the most stable and purpose-driven healthcare systems in the country. For manufacturers seeking a stable, high-adherence pati

Bottom Line: Pharmaceutical manufacturers of lung cancer therapies or adjacent therapies must orient their market access strategy toward...

Revolve Access is pleased to partner with Life Science Leader  on a recently published article, “ An Updated View of the Federal Segment...

Bottom Line: Integration of medical devices into VA telehealth appointments as core component of care creates a market opportunity for medical device manufacturers to become strategic partners in a national, unified healthcare system. The Department of Veterans Affairs’ (VA) dedication to innovative solutions in serving the unique needs of its veteran population is perhaps most evident in its approach to telehealth. Unlike commercial health systems that generally offer telehe

Bottom Line: The VA and DoD collaborate strategically on pharmaceutical management, leveraging their buying power, pooling resources in...

Bottom Line: The VA's Non-Formulary (NF) designation can be overcome through broad, compelling clinical justification demonstrating...

The Defense Health Agency’s Benefits Advisory Panel (BAP) has long served as a gatekeeper in the military health system’s formulary...